The Effect of PTPRδ rs17584499 C/T Polymorphism on Therapeutic Efficacy of Metformin in Chinese Patients with Type 2 diabetes

Abstract

Aim: To investigate whether the protein tyrosine phosphates receptor type delta gene (PTPRδ) rs17584499 C/T genetic polymorphism is associated with development of type 2 diabetes mellitus (T2DM) and metformin therapeutic efficacy in Chinese T2DM patients. Methods: A case-control study of 402 T2DM patients and 171 healthy controls was conducted to identify the genotypes for PTPRδ rs17584499 polymorphism using the ABI 3700 automatic sequence assay. 44 first-onset T2DM patients were selected to orally 500 mg metformin daily for 12 consecutive weeks as monotherapy. Serum fasting plasma glucose (FPG), Postprandial Plasma Glucose (PPG), Glycated Hemoglobin (HbA1c), Fasting Serum Insulin (FINS), Postprandial Serum Insulin (PINS), Triglycerol (TG), Cholesterol (CHO), Low-Density Lipoprotein (LDL-c), High-Density Lipoprotein Cholesterol (HDL-c), and Homeostasis Model Assessment for Insulin Resistance (HOMA-IR), Body Mass Index (BMI) were determined before and after metformin treatment. Results: There were no significant differences in the allelic frequencies of the PTPRδ rs17584499 C/T polymorphism between T2DM patients and healthy controls. After metformin treatment, the values of BMI, FPG, PPG, PINS, HbAlc, CHO, and TG in T2DM patients significantly decreased ( P <0.01, respectively), while markedly increased FINS (P <0.001). Metformin significantly decreased the levels of PPG ( P <0.05) and CHO (P <0.05) of patients with PTPRδ rs17584499 CT+TT genotypes compared of individuals with CC genotype. Conclusion: PTPRδ rs17584499 C/T polymorphism may not be associated with the risk of T2DM. But it may affect the PPG, HbAlc, and CHO in Chinese T2DM patients with metformin monotherapy.